Endocyte, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
Published: May 31, 2012
WEST LAFAYETTE, Ind., May 31, 2012 (GlobeNewswire via COMTEX) - Endocyte, Inc., a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Ron Ellis, president and CEO of Endocyte, will present at the upcoming Jefferies 2012 Global Healthcare Conference on Thursday, June 7, at 12:30 p.m. EDT. The conference is being held in New York.
A live audio webcast of the Company's presentation can be accessed at http://wsw.com/webcast/jeff68/ecyt/ or in the Investor Relations section of the Company's website at www.endocyte.com. The webcast will be archived shortly after the live event and a replay will be available on the Company's website for 90 days following the conference.
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Endocyte, Inc.
CONTACT: Stephanie Ascher Stern Investor Relations, Inc. (212) 362-1200 email@example.com Martina Schwarzkopf, Ph.D. Russo Partners (212) 845-4292 firstname.lastname@example.org Tony Russo, Ph.D. Russo Partners (212) 845-4251 email@example.com